Table 1.
Fluorescence characteristics of all tumour sites stratified by lesion type
| No. of patients* | No. of lesions | TP | FN | FP | TBR†‡ | Occult lesions identified with FLI* | Figure | |
|---|---|---|---|---|---|---|---|---|
| Primary tumours | 16 (94) | 17 | 0 (0) | 17 (100) | 0 (0) | 1.10 (1.00–1.13) | 0 (0) | S1 |
| Multiple primaries | 8 (47) | 43 | 0 (0) | 43 (100) | 0 (0) | 1.16 (1.04–1.18) | 0 (0) | – |
| Peritoneal metastases | 4 (24) | 82 | 76 (94) | 5 (6) | 0 (0) | 1.88 (1.70–2.05) | 3 (18) | 1 |
| Liver metastases | 2 (12) | 14 | 13 (93) | 1 (7) | 0 (0) | 2.13 (1.89–2.46) | 0 (0) | 1 |
| Mesenteric masses | 13 (76) | 13 | 11 (85) | 2 (15) | 0 (0) | 1.91 (1.60–2.12) | 0 (0) | S3 |
| Lymph nodes | 4 (24) | 6 | 1 (17) | 0 (0) | 5 (83) | 1.78 | 1 (6) | S5 |
Values are n (%) with respect to lesions unless indicated otherwise; *values in parentheses are percentage of patients; †values are median (i.q.r.). ‡Benign lesions (false-positives) were excluded from tumour-to-background ratio (TBR) analysis. Note: As clinically unsuspected, fluorescence-negative tissue was not biopsied, true-negatives could not be assessed. TP, true-positives; FP, false-positives; FN, false-negatives; FLI, fluorescence imaging.